Trial reportBritish journal of cancer2015
Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.
Trial report in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Trial
- Serum Concentrations of Selected Biological Factors as a Potential Tool for Detecting Recurrence in Endocrine Tumors-A Pilot Study.Journal of clinical medicine · 2025Article
- Characterization of the Pancreatic Neuroendocrine Neoplasm Immune Microenvironment.Cancer medicine · 2025Review
- Biochemical Markers for Neuroendocrine Tumors: Traditional Circulating Markers and Recent Development-A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Article
- Circulating Angiogenic Markers in Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review.Current issues in molecular biology · 2022Review
- Review
- Translational challenges in pancreatic neuroendocrine tumor immunotherapy.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?Frontiers in endocrinology · 2021Review
- Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs).Therapeutic advances in medical oncology · 2021Review
- Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.World journal of gastroenterology · 2020Review
- Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms.Endocrine connections · 2019Article
- Carcinoid heart disease involving the left heart: a case report and biomarker analysis.ESC heart failure · 2019Article
- Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib.Oncotarget · 2018Article
- Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors.Molecular cancer therapeutics · 2018Article
- Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Review
- Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.Targeted oncology · 2017Review
- Review
- Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.Nature reviews. Clinical oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundSunitinib is approved worldwide for treatment of advanced pancreatic neuroendocrine tumours (pNET), but no validated markers exist to predict response. This analysis explored biomarkers associated with sunitinib activity and clinical benefit in patients with pNET and carcinoid tumours in a phase II study.
methodsPlasma was assessed for vascular endothelial growth factor (VEGF)-A, soluble VEGF receptor (sVEGFR)-2, sVEGFR-3, interleukin (IL)-8 (n=105), and stromal cell-derived factor (SDF)-1α (n=28). Pre-treatment levels were compared between tumour types and correlated with response, progression-free (PFS), and overall survival (OS). Changes in circulating myelomonocytic and endothelial cells were also analysed.
resultsStromal cell-derived factor-1α and sVEGFR-2 levels were higher in pNET than in carcinoid (P=0.003 and 0.041, respectively). High (above-median) baseline SDF-1α was associated with worse PFS, OS, and response in pNET, and high sVEGFR-2 with longer OS (P⩽0.05). For carcinoid, high IL-8, sVEGFR-3, and SDF-1α were associated with shorter PFS and OS, and high IL-8 and SDF-1α with worse response (P⩽0.05). Among circulating cell types, monocytes showed the largest on-treatment decrease, particularly CD14+ monocytes co-expressing VEGFR-1 or CXCR4.
conclusionsInterleukin-8, sVEGFR-3, and SDF-1α were identified as predictors of sunitinib clinical outcome. Putative pro-tumorigenic CXCR4+ and VEGFR-1+ monocytes represent novel candidate markers and biologically relevant targets explaining the activity of sunitinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.